Infectious Disease Reports
Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin Ezetimibe
By Katia Falasca, Claudio Ucciferri, Damiano D’Ardes and 6 others.
Abstract
Background
People living with HIV (PLWH) have increased cardiovascular disease risk, and dyslipidemia remains a major modifiable factor. Achieving recommended low-density lipoprotein cholesterol (LDL-C) targets can be challenging.
Objective
To evaluate the real-world effectiveness and safety of fixed-dose low-dose rosuvastatin/ezetimibe in virologically stable PLWH and to describe lipid-lowering kinetics in comparison with an HIV-negative control cohort.
Methods
This retrospective single-center study included 32 PLWH and 43 HIV-negative outpatients receiving rosuvastatin 5 mg plus ezetimibe 10 mg daily. Lipid parameters, cardiovascular risk scores, and safety markers were assessed at baseline, 3 months, and 6 months.